+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Castleman’s Disease and Mesangial Proliferative Glomerulonephritis: The Role of Interleukin-6

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Renal complications of Castleman’s disease (angiofollicular lymph node hyperplasia) are uncommon. The reported cases are very heterogeneous and their renal pathology ranged from minimal change disease, mesangial proliferative glomerulonephritis, to amyloidosis. We have previously reported two cases of Castleman’s disease with renal complications. We now present two more such cases. In contrast to other reports, all our cases are of the plasma cell type and their renal pathology showed remarkable similarities, namely mesangial proliferation, interstitial plasma cell infiltration and negative immunofluorescence. The level of serum interleukin-6 (IL-6) in both patients was elevated at presentation and came down with immunosuppressive therapy.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: found
          • Article: not found

          Biological and clinical aspects of interleukin 6.

          Interleukin 6 (IL-6) is a multi-functional cytokine that is produced by a range of cells and plays a central role in host defense mechanisms. Abnormal production of IL-6 has been suggested to be involved in glomerulonephritis, plasmacytomagenesis and in the pathogenesis of autoimmune diseases. In this review, Toshio Hirano and colleagues discuss the possible involvement of IL-6 in a variety of diseases, the regulatory mechanism(s) of expression of the IL-6 gene and the structure and function of the IL-6 receptor.
            • Record: found
            • Abstract: not found
            • Article: not found

            Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.


              Author and article information

              S. Karger AG
              March 1998
              25 February 1998
              : 78
              : 3
              : 323-327
              a Division of Nephrology, Department of Medicine, and b Department of Pathology, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
              44943 Nephron 1998;78:323–327
              © 1998 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Figures: 2, Tables: 1, References: 26, Pages: 5
              Self URI (application/pdf):
              Short Communication


              Comment on this article